Gene, Cell, & RNA Therapy Landscape Report

The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Informa Pharma Intelligence, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Q2: Approved GTs are first for their indications

In Q2 2023:

  • Six therapies were approved, including two gene therapies, Elevidys and Vyjuvek, that were the first to be approved for their respective indications

  • Roctavian was approved in the U.S.

  • More gene therapies moved into Phase II trials in the past quarter than have in more than a year 

Report Archives

2023 Archive

Read all the landscape reports from 2023.

2022 Archive

Read all the landscape reports from 2022.

2021 Archive

Read all the reports from 2021 here.


ASGCT Policy Summit

Watch on demand through Oct. 23!

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.